Wire · opportunities
FDA Approves New Pill For Advanced Breast Cancer Guided By Blood Test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 September 2026 · Fusion42 review
The FDA has approved Etcamah (camizestrant), a new pill for adults with advanced hormone receptor-positive, HER2-negative breast cancer resistant to current treatments, alongside a blood test (Guardant360 CDx) that detects gene changes signaling resistance before disease progression is visible on scans.
This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 4 Sep 2026 and 8 Sep 2026.
◆ ◆ The Wire takeaway
You need to move faster on treatment innovation because the FDA just approved a new cancer drug paired with a blood test that spots resistance earlier. This opens an urgent path for diagnostics and tailored therapies to enter care sooner and outpace outdated waiting strategies.
◆ Coverage
12 sources · first reported 4 Sep 2026 · latest 8 Sep 2026
◆ Related on Wire
◆ Topics